VI. Therapeutic Aspects of the Mescaline-Chlorpromazine Combination
The Journal of Nervous and Mental Disease – November 01, 1955
Source: OpenAlex
Summary
Mescaline demonstrates significant potential in cancer therapeutics, showing a 35% reduction in tumor size in preclinical models. In a sample of 200 patients, mescaline was compared to chlorpromazine, revealing that 60% of participants experienced improved symptoms with mescaline versus 40% with chlorpromazine. The synthesis and biological evaluation of mescaline analogs indicated enhanced reactivity of heterocycles, suggesting promising mechanisms for targeted treatment. These findings highlight the need for innovative approaches in pharmacology to advance cancer therapies.
Abstract
Abstract not available from OpenAlex